News
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
A new variation of the CRISPR-Cas9 gene editing system makes it easier to re-engineer massive quantities of cells for therapeutic applications. The approach, developed at Gladstone Institutes and UC San Francisco (UCSF), lets scientists introduce especially long DNA sequences to precise locations in
Giving Immunotherapy Cells Resilience to Pass the “Stress Test”
T cells used in immunotherapy treatments can get exhausted by the task of fighting cancer cells or get shutdown as they enter tumors. Using a CRISPR-based edit on these cells’ genomes, researchers at UC San Francisco and Gladstone Institutes have rendered the therapeutic cells more resilient. The
New Pediatric Tumor Identifications Could Help Predict Chemo Response
A new UC San Francisco study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment. The study, publishing in Nature Communications on August 25, used single-cell transcriptomic techniques to analyze
Trial Library Emerges Out of Stealth with $5 Million in Seed Funding
Trial Library, Inc., an oncology clinical trials company, today announced it has come out of stealth mode and received its first funding to address the need for equity in patient recruitment to oncology clinical trials. The $5 million seed round was led by Deena Shakir, Partner at Lux Capital, with
Abortion Ban May Increase the Risk of Death for Pregnant Women with Cancer
Watch the video below from ABC7 News.